Almaty, Kazakhstan, 13 July 2025 – MicroPort® CardioFlow has announced the first commercial implantations of its VitaFlow Liberty® Transcatheter Aortic Valve Implantation (TAVI) system in Kazakhstan. A total of four patients were treated at the JSC "Research Institute of Cardiology and Internal Diseases" in Almaty, one of the country’s leading centers for cardiovascular care.
The procedures were led by Dr. Alexey, a leading cardiologist in Kazakhstan, and jointly performed with Chinese specialists including Prof. Mao Chen and Prof. Yuan Feng from West China Hospital of Sichuan University.
VitaFlow Liberty® builds upon the proven design of its predecessor, VitaFlow®, incorporating a hybrid-density self-expanding stent, bovine pericardial leaflets, and an advanced double-layer PET skirt. These features provide strong radial support, improved coaxial deployment, and reduced perivalvular leakage post-procedure. Furthermore, its next-generation delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.
Dr. Alexey noted, “The system offers greater control and flexibility during implantation, with excellent clinical precision. We look forward to continued collaboration to advance transcatheter techniques.”
About MicroPort® CardioFlow
Founded in 2015, MicroPort® CardioFlow (MicroPort® CardioFlow Medtech Corporation, HKEX: 02160) is a leading medical device company focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart disease.
MicroPort® CardioFlow’s self-developed transcatheter aortic valve implantation series products are successfully used in more than 700 core hospitals worldwide. In addition, MicroPort® CardioFlow has established a strategic research and development pipeline covering TAVI (transcatheter aortic valve treatment) products, left atrial appendage closure systems, transcatheter mitral valve treatment products, transcatheter tricuspid valve treatment products, and surgical accessories through in-house development and collaboration with global partners. MicroPort® CardioFlow is committed to providing total solutions for structural heart diseases, delivering high-quality therapeutic solutions to patients and physicians across the globe.
More information is available at: https://en.cardioflowmedtech.com/